Hyperbaric oxygen in the treatment of sudden... (2003 study) Skip to main content
Retrospective Study ORL; journal for oto-rhino-laryngology and its related specialties 2003

Hyperbaric oxygen in the treatment of sudden hearing loss.

Racic G, Maslovara S, Roje Z, Dogas Z, Tafra R, ORL; journal for oto-rhino-laryngology and its related specialties, 2003

Tier 2, Indexed

Automatically imported from PubMed based on relevance criteria.

Summary

What Researchers Did

The researchers looked back at the records of 115 people with sudden hearing loss of unknown cause and compared two treatments: hyperbaric oxygen (HBO) and pentoxifylline infusions.

What They Found

This retrospective study of 115 patients with idiopathic sudden hearing loss found larger hearing gains in the 51 patients treated mainly with HBO at 2.8 bar than in the 64 patients given pentoxifylline infusions. Average hearing improved by 46.35 dB hearing level (SD 18.58) with HBO and by 21.48 dB hearing level (SD 13.5) with pentoxifylline, with p less than 0.001. Hearing returned to normal values in 24 of 51 HBO patients (47.1%) and 4 of 64 pentoxifylline patients (6.2%). Partial recovery was seen in 8 of 64 pentoxifylline patients (12.5%), while 21 of 51 HBO patients (41.2%) improved to a mild persistent hearing loss.

What This Means for Canadian Patients

For people with sudden hearing loss of unknown cause, this study reports better hearing results in the group treated with HBO than in the group given pentoxifylline. The patients were not randomly assigned to treatment, so the groups may have differed in ways the abstract does not describe. The authors say more prospective clinical trials are needed to confirm how well HBO works.

Canadian Relevance

No direct Canadian connection identified.

Study Limitations

The study was retrospective, with patients who were not randomly assigned to treatment, so the abstract's comparison cannot show that HBO caused the better results, and the authors themselves call for prospective trials.

This plain-language summary was generated with AI assistance from the study's abstract; it has not been individually reviewed by a clinician. Always consult the source study and a qualified healthcare professional. See our editorial policy.

Was this summary helpful?

Study Details

Study Type Retrospective Study
Category Sudden Hearing Loss
Source Pubmed
PubMed ID 14981323
Year Published 2003
Journal ORL; journal for oto-rhino-laryngology and its related specialties
MeSH Terms Audiometry, Pure-Tone; Auditory Threshold; Female; Hearing Loss, Sudden; Humans; Hyperbaric Oxygenation; Infusions, Intravenous; Male; Middle Aged; Pentoxifylline; Retrospective Studies; Treatment Outcome; Vasodilator Agents

Cite This Study

Share

This study relates to Sudden Sensorineural Hearing Loss. Read the full clinical overview, the evidence base, and Canadian treatment access for this condition.

Find a Canadian Clinic Treating Sudden Hearing Loss

Browse verified hyperbaric facilities across Canada.

View Canadian Facilities

Disclaimer: This study summary is provided for informational and educational purposes only. It does not constitute medical advice. The information presented reflects the findings of the original research authors and may not represent the views of Canada Hyperbarics. Always consult a qualified healthcare professional before making treatment decisions.

Last updated: April 1, 2026 | Reviewed by: Canada Hyperbarics Editorial Team | Editorial process | Research sources | Counts & methodology